SR T100

Drug Profile

SR T100

Alternative Names: SR-T100; SR-T100 gel

Latest Information Update: 29 Jun 2016

Price : $50

At a glance

  • Originator G&E Herbal Biotechnology
  • Class Antineoplastics; Phytotherapies
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Actinic keratosis
  • Phase II Condylomata acuminata
  • Phase 0 Vulvar intraepithelial neoplasia

Most Recent Events

  • 01 Nov 2015 G&E Herbal Biotechnology completes a phase III trial in Actinic keratosis in Taiwan (Topical, gel) (NCT01493921)
  • 30 Sep 2015 G&E Herbal Biotechnology plans a pharmacokinetics phase I trial for Actinic keratosis in Taiwan (Topical) (NCT02559934)
  • 09 Mar 2015 SR T100 is still in phase III trials for Actinic keratosis in Taiwan (Topical, gel)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top